Targeting Nrf2 for the treatment of Duchenne Muscular Dystrophy

Area of Science:

• Biochemistry
• Molecular Biology
• Pathology

Background:

• Oxidative stress and redox homeostasis imbalances are implicated in Duchenne Muscular Dystrophy (DMD).
• DMD presents multiple cellular and molecular pathologies, including muscle degeneration, mitochondrial dysfunction, and inflammation.
• Previous therapeutic approaches targeting single DMD pathologies have shown limited efficacy.

Purpose of the Study:

• To review the literature on targeting the Nrf2 pathway as a disease-modifying treatment for DMD.
• To provide a theoretical basis for Nrf2 activation as a therapeutic strategy for DMD.

Main Methods:

• Literature review of studies investigating redox homeostasis, oxidative stress, and Nrf2 in DMD.
• Analysis of Nrf2's role in regulating cytoprotective genes.
• Evaluation of Nrf2's potential to modulate multiple DMD pathological pathways.

Main Results:

• Nrf2 is a key transcription factor that upregulates cytoprotective genes in response to stressors.
• Targeted Nrf2 activation can simultaneously address diverse pathological features of DMD.
• This approach holds potential for amplified therapeutic benefits compared to single-target strategies.

Conclusions:

• Nrf2 activation represents a promising, multi-targeted therapeutic strategy for Duchenne Muscular Dystrophy.
• Modulating Nrf2 offers a novel approach to disease modification in DMD.
• Further research into Nrf2-targeted therapies is warranted for DMD treatment.